Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved overall and event-free survival in patients 18 to 59 years of age with FLT3-mutated acute myeloid leukemia (AML). Howev...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Schmalbrock, Laura K., Dolnik, Anna, Cocciardi, Sibylle, Sträng, Eric, Theis, Frauke, Jahn, Nikolaus, Panina, Ekaterina, Blätte, Tamara J., Herzig, Julia, Skambraks, Sabrina, Rücker, Frank G., Gaidzik, Verena I., Paschka, Peter, Fiedler, Walter, Salih, Helmut R., Wulf, Gerald, Schroeder, Thomas, Lübbert, Michael, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Larson, Richard A., Ganser, Arnold, Stunnenberg, Hendrik G., Minucci, Saverio, Stone, Richard M., Bloomfield, Clara D., Döhner, Hartmut, Döhner, Konstanze, Bullinger, Lars
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2021
Aiheet:
Myeloid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8233666/
https://ncbi.nlm.nih.gov/pubmed/33598693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007626
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia